Nicotine treatment alters NF-κB expression in human cytomegalovirus-infected ARPE-19 cells

Current Eye Research

Volumn 31, Issue 2, 2006, Pages 191-198

  Buckner, Anissa ^a   Dix, Richard ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

ARPE 19 cells; Human cytomegalovirus; NF B; Nicotine; Retinal pigment epithelium

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; NICOTINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; INOCULATION; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA CELL; VIRUS INHIBITION; VIRUS REPLICATION;

BLOTTING, WESTERN; CELL LINE; CYTOMEGALOVIRUS; GENE EXPRESSION; HUMANS; NF-KAPPA B; NICOTINE; NICOTINIC AGONISTS; PIGMENT EPITHELIUM OF EYE; TRANSFECTION; VIRUS REPLICATION;

EID: 33644623816     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680500514651     Document Type: Article

References (55)

1. Villablanca AC, McDonald JM, Rutledge JC. Smoking and cardiovascular disease. Clin Chest Med. 2001;21:159-172.
2. Kilaru S, Frango SG, Chen AH, et al. Nicotine: a review of its role in atherosclerosis. J Am Coll Surg. 2001;193:538-546.
3. Conklin BS, Zhao W, Zhong D-S, Chen C. Nicotine and cotinine upregulate vascular endothelial growth factor expression in endothelial cells. Am J Pathol. 2002;160:413-418.
4. Lakier JB. Smoking and cardiovascular disease. Am J Med. 1992;3:8S-12S.
5. Mogensen TH, Paludan SR. Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev. 2001;65:131-150.
6. Grilli M, Chiu JJ, Lenardo MJ. NF-kappa B and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol. 1993;143:1-62.
7. Mocarski ES, Courcelle CT. Cytomegaloviruses and their replication. In: Knipe DM, Howley PM. Fields Virology. Philadelphia: Lippincott, Williams & Wilkins; 2001:2629-2673.
8. Baldwin AS. The transcription factor NF-κB and human disease. J Clin Invest. 2001;107:3-5.
9. Sen R, Baltimore D. Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a post-translational mechanism. Cell. 1986;47:921-928.
10. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3:221-227.
11. Baeuerle PA. The inducible transcription activator NF-κB: regulation by distinct protein subunits. Biochem Biophys Acta 1991;1072:63-80.
12. Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J. 1989;8:4251-4258.
13. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
14. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260.
15. Pahl HL. Activators and target genes of REL/NFκ-B transcription factors. Oncogene. 1999;18:6853-6866.
16. Santoro MG, Rossi A, Amici C. NF-κB and virus infection: who controls whom. EMBO. 2003;22:2552-2560.
17. Krajcsi P, Wold WSM. Viral proteins that regulate cellular signalling. J Gen Virol. 1998;79:1323-1335.
18. Havard L, Delvenne P, Frare P, Boniver J, Giannini SL. Differential production of cytokines and activation of NF-κB in HPV-transformed keratinocytes. Virology. 2002;298:271-285.
19. Jarvis MA, Nelson JA. Human cytomegalovirus persistence and latency in endothelial cells and macrophages. Curr Opin Microbiol. 2002;5:403-407.
20. Söderberg-Nauclér C, Fish KN, Nelson JA. Growth of human cytomegalovirus in primary macrophages. Methods. 1998;16:126-138.
21. Holland GN, Tufail A, Jordan MC. Cytomegalovirus diseases. In: Pepose JS, Holland GN, Wilhelmus KR. Ocular Infection & Immunity. St. Louis, MO: Mosby;1996:Chap. 81:1088-1128.
22. Besancon-Watelet C, De March AK, Renoult E, et al. Early increase of peripheral B cell levels in kidney transplant recipients with CMV infection or reactivation. Transplantation. 2000;69:366-371.
23. Sweet C. The pathogenicity of cytomegalovirus. Micro Rev. 1999;23:457-482.
24. DeMeritt IB, Milford LE, Yurochko AD. Activation of the NF-κB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter. J Virol. 2004;78:4498-4507.
25. Dix RD, Cray C, Cousins S. Cytomegalovirus retinitis during AIDS: current issues and future directions. Reg Immunol. 1994;6:112-118.
26. Detrick B, Rhame J, Wang Y, et al. Cytomegalovirus replication in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1996;37:814-825.
27. Cinatl J, Margraf S, Vogel J-U, et al. Human cytomegalovirus circumvents NF-κB dependence in retinal pigment epithelial cells. J Immunol. 2001;167:1900-1908.
28. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res. 1996;62:155-169.
29. Cha TA, Tom E, Kemble GW, et al. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol. 1996;70:78-83.
30. Bone DR, Courtney RJ. A temperature-sensitive mutant of herpes simplex virus type 1 defective in the synthesis of the major capsid polypeptide. J Gen Virol. 1974;24:17-27.
31. Neuwelt EA, Pagel MA, Dix RD. Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier. J Neurosurg. 1991;74:475-479.
32. Kowalik TF, Wing B, Haskill JS, et al. Multiple mechanisms are implicated in the regulation of NF-kappa B activity during human cytomegalovirus infection. Proc Natl Acad Sci USA. 1993;90:1107-1111.
33. Yurochko AD, Kowalik TF, Huong SM, Huang ES. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters. J Virol. 1995;69:5391-5400.
34. Zidovetzki R, Chen P, Fisher M, Hofman FM. Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C- associated pathway. Stroke. 1999;30:651-655.
35. Buckner AE, Tesmer VM, Bina M. Regulation of HIV-1 transcription by NF-IL6 in activated Jurkat T cells. Virus Res. 2002;89:53-63.
36. de Lucas S, Bartolome J, Amaro MJ, Carreno V. Hepatitis C virus core protein transactivates the inducible nitric oxide synthase promoter via NF-kappaB activation. Antiviral Res. 2003;60:117-124.
37. Söderberg-Nauclér C, Nelson JA. Human cytomegalovirus latency and reactivation - a delicate balance between the virus and its host's immune system. Intervirology. 1999;42:314-321.
38. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci U S A. 1994;91:11879-11883.
39. Pass RF. Cytomegalovirus. In: Knipe DM, Howley PM. Fields Virology, Philadelphia, Lippincott Williams & Wilkins; 2001:2675-2705.
40. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: Emerging mechanistic paradigms. Circulation. 1999;100:e20-e28.
41. Fish KN, Söderberg-Nauclér C, Mills LK, et al. Human cytomegalovirus persistently infect aortic endothelial cells. J Virol. 1998;72:5661-5668.
42. Miller DM, Legra J, Dubovy SR, et al,. The association of prior cytomegalovirus infection with neovascular age-related macular degeneration. Am J Ophthalmol. 2004;138:323-328.
43. Stenberg RM. The human cytomegalovirus major immediate-early gene. Intervirology. 1996;39:343-349.
44. Treichel JL, Henry MM, Skumatz CM, et al. 2Formate, the toxic metabolite of methanol, in cultured ocular cells. Neurotoxicology. 2003;24:825-834.
45. Blackburn J, Tarttelin EE, Gregory-Evans CY, et al. Transcriptional regulation and expression of the dominant drusen gene FBLN3 (EFEMP1) in mammalian retina. Invest Ophthalmol Vis Sci. 2003;44:4613-4621.
46. Kimoto K, Nakatsuka K, Matsuo N, Yoshioka H. p38 MAPK mediates the expression of type I collagen induced by TGF-beta 2 in human retinal pigment epithelial cells ARPE-19. Invest Ophthalmol Vis Sci. 2004;45:2431-2437.
47. Le Novere N, Corringer PJ, Changeux JP. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. Neurobiology. 2002;53:447-456.
48. van Dyk LF, Virgin HW 4th, Speck SH. The murine gammaherpesvirus 68 v-cyclin is a critical regulator of reactivation from latency J Virol. 2000;74:7451-7461.
49. Hsich E, Zhou YF, Paigen B, et al. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis. 2001;156:23-28.
50. Duan Y, Ji Z, Atherton SS. Dissemination and replication of MCMV after supraciliary inoculation in immunosuppressed BALB/c mice. Invest Ophthalmol Vis Sci. 1994;35:1124-1131.
51. Stagno S, Reynolds DW, Amos CS, et al. Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics. 1977;59:669-678.
52. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3586-3592.
53. Bruggeman CA, Marjorie HJ, Nelissen-Vrancken G. Cytomegalovirus and atherogenesis. Antiviral Res. 1999;43:191-200.
54. Yoshida S, Yoshida A, Ishibashi T. Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation. Graefes Arch Clin Exp Ophthalmol. 2004;242:409-413.
55. Cousins SW, Csaky KG. Immunology of age-related macular degeneration. In: Lim JI. Age-Related Macular Degeneration. New York: Marcel Dekker, Inc; 2002;27-65.